Download PDF
Thromb Haemost 2001; 85(05): 940-941
DOI: 10.1055/s-0037-1615775
Letters to the Editor
Schattauer GmbH

Extended Thromboprophylaxis with Low Molecular Weight Heparin Reduces Symptomatic Venous Thromboembolism following Lower Limb Arthroplasty - a Meta-analysis

A. T. Cohen
1   Academic Department of Surgery
,
C. S. Bailey
1   Academic Department of Surgery
,
R. Alikhan
1   Academic Department of Surgery
,
D. J. Cooper
2   Computing Services, Guy‘s, King‘s and St. Thomas‘s School of Medicine and Dentistry, London, UK
› Author Affiliations
Further Information

Publication History

Received 02 November 2001

Accepted after resubmission 16 January 2001

Publication Date:
11 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-8.
    CrossrefPubMedGoogle Scholar
  • 2 Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, Nelsson P, Nylander G. Low-molecular-weight heparin (enoxaparin) as prophylaxis against thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
    CrossrefPubMedGoogle Scholar
  • 3 Dahl OE, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S, Abdelnoor M, Solhaug JH, Arnesen H. Prolonged thromboprophylaxis following hip replacement surgery - results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin®). Thromb Haemost 1997; 77: 26-31.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejo Bro HP, Anderson G, Peterson AO, Siem P, Horlyck E, Jensen BV, Thomsen PB, Hansen BR, Erin-Madsen J, Moller JC, Rotwitt L, Christensen F, Nielsen JB, Jorgensen PS, Paaske B, Torholm C, Hvidt P, Jensen NK, Nielsen AB, Appelquist E, Tjalve E. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res 1998; 89: 281-7.
    CrossrefPubMedGoogle Scholar
  • 5 Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R. Low-molecular weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med. 2000; 160 (Suppl. 14) 2208-15.
    CrossrefPubMedGoogle Scholar
  • 6 Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. for the Ardeparin Arthroplasty Study Group. Ardeparin Sodium for extended out-of-hospit l prophyl xis g inst venous thromboembolism fter tot l hip or knee replacement. A randomised, double-blind, placebo-controlled trial. Ann Intern Med. 2000; 132: 853-61.
    PubMedGoogle Scholar